Chikungunya virus envelope protein complex (CHIKV E proteins)

The Chikungunya virus (CHIKV) envelope proteins, specifically the E1 and E2 glycoproteins, form icosahedral spikes on the virion surface that are critical for the viral life cycle (UniProt P08491). The E2 protein facilitates attachment to host cell receptors, such as the Matrix Remodeling Associated 8 (Mxra8) protein, while the E1 protein acts as a class II fusion protein that mediates the fusion of the viral envelope with the host endosomal membrane (Zhang et al., 2018, Nature). These proteins are the primary targets for neutralizing antibodies and are the central components of vaccine strategies, including the FDA-approved live-attenuated vaccine Ixchiq (FDA, 2023). Therapeutic interventions often focus on blocking the E2-receptor interaction or inhibiting the pH-triggered conformational change in E1 required for fusion (Voss et al., 2010, Nature). Understanding the structural dynamics of these proteins is essential for developing broad-spectrum antivirals against CHIKV and related alphaviruses. Mutations in the envelope proteins, such as E1-A226V, have been shown to significantly alter vector specificity and epidemic potential (Tsetsarkin et al., 2007, PLoS Pathogens).

Other names

CHIKV E1/E2/E3Chikungunya virus spike proteinsEnvelope glycoproteins

Neutralization of viral entry by blocking receptor binding or preventing pH-dependent membrane fusion.